How MediChip™ Works
.svg)
MediChip™ is designed to interface directly with solid tumors across multiple anatomical sites.
MediChip™ is designed to interface directly with solid tumors across multiple anatomical sites.
MediChip™ is designed to interface directly with solid tumors across multiple anatomical sites.
MediChip™ is designed to interface directly with solid tumors across multiple anatomical sites.
Why Localized Delivery?
Systemic delivery limits the dose.
Local placement changes the equation.
The platform is agent-agnostic.
Platform Technology
Why It Matters
.svg)
Platform Advantages
Lower GI Cancers
Our current focus is lower GI cancers (colorectal), where MediChip™ has demonstrated strong preclinical performance. The platform's adaptability positions it for expansion across multiple oncology indications.
Future Platform Opportunities
Oncology
Where the platform is being actively evaluated.
Animal Health
Mention exploration without making it feel like a second company.
Future Expansion Opportunities
Where the platform is being actively evaluated.
Frequently Asked Questions
Cytotoxic agents are dosed to what the whole body can tolerate, not to what the tumor requires. Toxicity to healthy tissue sets the ceiling.
Delivering therapy directly at the tumor bed decouples local concentration from systemic exposure — sustained release over weeks from a single placement.
The delivery architecture is not specific to one drug. It is designed to carry a range of therapeutic payloads across solid tumor indications.
The delivery architecture is not specific to one drug. It is designed to carry a range of therapeutic payloads across solid tumor indications.
The delivery architecture is not specific to one drug. It is designed to carry a range of therapeutic payloads across solid tumor indications.
The delivery architecture is not specific to one drug. It is designed to carry a range of therapeutic payloads across solid tumor indications.
.png)
.png)
Help shape the future of localizedcancer therapy.
Whether you're a pharmaceutical company, research institution, clinical investigator, or strategic partner, we're building the next generation of localized oncology treatments together.
.avif)